6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders

A compound of formula (I)

• wherein
• R1 is a 5 or 6 membered heteroaryl-group whereby 1, 2, 3 or 4 of the ring atoms are heteroatoms that are selected independently of each other from N, O or S,
• whereby said 5 or 6 membered aromatic heteroaryl-group optionally may be substituted by 1, 2, 3 or 4 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, HO—, NC—, F3C—, HF2C—, FH2C—, methyl, H2N— and (CH3)2N—;
• R2 is selected from the group consisting of fluorine, NC—, F3C—, HF2C—, FH2C— and methyl;
• D is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl,
• whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, NC—, F3C—, HF2C— and FH2C—;
• whereby tetrahydrofuranyl and tetrahydropyranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, NC—, F3C—, HF2C— and FH2C—;
• whereby pyridyl optionally may be substituted by 1, 2, 3 or 4 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC—, F3C—, HF2C—, FH2C—, F3C—CH2—, C1-6-alkyl- and C3-7-cycloalkyl,
• m is selected from 1 or 2;
• n is selected from 0, 1 or 2,
• whereby if n=2, two R2 groups are selected independently of one another;
• or a pharmaceutically acceptable salt thereof;
• with the proviso that the compound is not
• be it in the form of any possible stereoisomer or a mixture of all or some thereof.